Royalty Pharma (RPRX) Net Income towards Common Stockholders Growth (3y) (2022 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) Net Income towards Common Stockholders Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Orix | 44.18 Bn | 44.51 Bn | 4.68 Bn | - |
| 2 | Royalty Pharma | 33.59 Bn | 35.70 Bn | - | -38.56% |
| 3 | Royal Gold | 21.14 Bn | 21.00 Bn | 390.45 Mn | 55.16% |
| 4 | OR Royalties | 6.88 Bn | 6.81 Bn | 82.22 Mn | 10,122.48% |
| 5 | Encore Capital | 2.11 Bn | 1.93 Bn | 455.04 Mn | - |
| 6 | Atlanticus Holdings | 1.41 Bn | 851.50 Mn | 686.46 Mn | - |
| 7 | Jefferson Capital | 1.18 Bn | 1.16 Bn | - | - |
| 8 | Lufax Holding | 1.04 Bn | -1.23 Bn | - | -43.43% |
| 9 | Upbound | 998.67 Mn | 893.37 Mn | 594.84 Mn | 35.23% |
| 10 | Metalla Royalty & Streaming | 942.93 Mn | 931.86 Mn | 4.75 Mn | -7.39% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -38.56% |
| Mar 31, 2026 | -2.75% |
| Dec 31, 2025 | 37.21% |
| Sep 30, 2025 | 26.31% |
| Jun 30, 2025 | -42.67% |
| Mar 31, 2025 | 50.25% |
| Dec 31, 2024 | 84.00% |
| Sep 30, 2024 | 53.77% |
| Jun 30, 2024 | -37.77% |
| Mar 31, 2024 | -26.55% |
| Dec 31, 2023 | 25.09% |
| Sep 30, 2023 | -41.96% |
| Jun 30, 2023 | -16.43% |
| Mar 31, 2023 | 67.11% |
| Dec 31, 2022 | -34.29% |
| Sep 30, 2022 | -20.58% |
| Jun 30, 2022 | 40.10% |